section name header

Information

(see also GP IIb/IIIa Inhibitors)

ABCIXIMAB is a GP IIb/IIIa inhibitor, used as an adjunct to PTCA or atherectomy to prevent acute cardiac ischemia complications in patients at high risk for abrupt closure of the treated coronary vessel. It is intended to be used with aspirin and heparin therapy. ABCIXIMAB is FDA approved for patients with non–Q-wave MI or unstable angina with planned PCI within 24 hours.

Dosage

0.25 mg/kg as an IV bolus, given 10 to 60 minutes before start of PTCA or atherectomy, followed by a continuous infusion of 10 mcg/min for 12 hours. (Continuous infusion is sometimes ordered at 0.125 mcg/kg/min for 12 hours.)

Precautions

  • Use a dedicated IV line with an in-line filter.
  • May cause bradycardia, thrombocytopenia, and increased risk of bleeding.